A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.

Nanfang Hospital, Southern Medical University

Status: Enrolling

Conditions: Nasopharyngeal Carcinoma; EBV Infection

Treatments: Diagnostic Test: Proteomics technology and liquid biopsy

Study type: Observational

Funder types: Other

Identifiers

NCT05682703

NFEC-2022-470

Details and patient eligibility

About

The transformation process of nasopharyngeal carcinoma is complex, so it is particularly important to explore the relationship between various disease states on its clinical pathway. Therefore, we carried out this study to explore the changes of plasma and urine metabolites at different stages during the occurrence and development of nasopharyngeal carcinoma.

Enrollment: 2,000 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• EBV virus infector: QPCR/EBV antibody, diagnosed as EBV infection patient with previous infection;
• Nasopharyngeal carcinoma patients:Patients diagnosed as nasopharyngeal carcinoma by pathological diagnosis (2018 WHO standard);
• Healthy people: Healthy people who have no history of nasopharynx related diseases or other known diseases that may affect blood lipid/protein metabolism and have been hospitalized in the Physical Examination Center of Southern Hospital.

Exclusion criteria

1. People who have a history of non research related liver diseases or other diseases known to affect blood metabolism (except for controlled type II diabetes);
2. Have a history of other malignant tumors, except for fully treated basal cell carcinoma or squamous cell carcinoma and cervical carcinoma in situ;
3. Diseases requiring long-term use of immunosuppressive drugs (including steroids), including but not limited to congenital or acquired immunodeficiency diseases or active central nervous system metastatic cancer, active infection or uncontrolled heart disease;
4. Suffer from other uncontrolled serious diseases at the same time, such as unstable heart disease requiring treatment, diabetes with unsatisfactory control (fasting blood glucose>1.5 × Upper limit of normal value), mental illness and severe allergic history.
5. BMI is less than 18 or more than 25. -

Trial design

2,000 participants in 3 patient groups

EBV virus infector

Description:

QPCR/EBV antibody, diagnosed as EBV infection patient

Treatment:

Diagnostic Test: Proteomics technology and liquid biopsy

nasopharyngeal carcinoma patients

Description:

Patients diagnosed as nasopharyngeal carcinoma by pathological diagnosis (2018 WHO standard)

Treatment:

Diagnostic Test: Proteomics technology and liquid biopsy

Healthy people

Description:

healthy people with no history of nasopharynx related diseases or other known diseases that may affect blood lipid/protein metabolism

Treatment:

Diagnostic Test: Proteomics technology and liquid biopsy